• TOT Biopharm reshuffled board and top leadership effective April 29, 2026, following a change in control tied to completion of voluntary general cash offers that left WuXi XDC as controlling shareholder.
• Shan Fu resigned as executive director and board chair; four other directors also stepped down, including non-executive director Weidong Liu.
• Jincai Li was appointed executive director and board chair; he is CEO of WuXi XDC and a senior vice president at WuXi Biologics.
• Xiaojie Xi joined as non-executive director; he is CFO and company secretary of WuXi XDC and previously served as CFO of Akeso.
• Board added three independent directors, including Bilibili CFO Xin Fan and life-science entrepreneur Ulf Grawunder, former CEO of NBE-Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12131300), on April 28, 2026, and is solely responsible for the information contained therein.